Opendata, web and dolomites

ESPS SIGNED

Epileptic Seizure Prediction System (ESPS) - Predicting and preventing epileptic seizures based on respiratory biofeedback & machine learning.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ESPS project word cloud

Explore the words cloud of the ESPS project. It provides you a very rough idea of what is the project "ESPS" about.

disrupt    predicting    disorders    received    ibreve    14b    decades    nature    intensity    personalize    pharmacological    patterns    patent    cycle    algorithm    regulatory    structured    lives    personalized    staggering    injuries    70    changed    obtain    introduction    trials    leave    shift    healthcare    seizure    literally    follow    prediction    drugs    cure    nervous    sent    patients    employment    calculates    methodology    pending    onset    hesitant    antiepileptic    elderly    caused    independent    feasibility    disrupts    epilepsy    clinical    desired    business    50m    detection    therapies    visits    hard    probability    majority    burden    boston    clinician    wearable    shared    risks    analyzes    harvard    entering    tracking    prone    14    respiratory    innovation    intervention    saving    unpredictable    stress    time    worldwide    life    machine    plan    caregiver    preventive    causes    despite    treatment    house    esps    week    care    pillars    homecare    reduces    patient    market    reducing    seizures    caretaking    children    alone    people    hospital    learning    introducing    reliably    alert    health    clinicians   

Project "ESPS" data sheet

The following table provides information about the project.

Coordinator
IBREVE LIMITED 

Organization address
address: GROUND FLOOR 8-9 MARINO MART FAIRVIEW
city: DUBLIN
postcode: D03 P590
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.epilepsy.ibreve.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBREVE LIMITED IE (DUBLIN) coordinator 50˙000.00

Map

 Project objective

Epilepsy is one of the most common nervous system disorders and affects more than 50M people worldwide. The majority of new-onset cases occur in elderly and children. Currently there is no cure for epilepsy. Although antiepileptic drugs can help, one third of all patients do not respond to any pharmacological intervention. This staggering number has not changed in decades, despite over 14 new therapies entering the market. The unpredictable nature of seizures causes the largest burden for patients as it literally disrupts their lives. Patients with several seizures a week are hesitant to leave the house & find it hard to obtain employment. Reliably predicting seizures enables an independent life for the patient and at the same time reduces healthcare costs caused by clinician visits, injuries & caretaking. iBreve’s new patent-pending wearable technology analyzes respiratory patterns in real-time, enabling market applications for seizure prediction, respiratory treatment & stress management. iBreve’s technology received interest from Harvard’s Boston Children’s Hospital to be included in clinical trials for seizure detection & prediction. The ESPS machine learning algorithm calculates seizure probability & intensity and if desired an alert is sent to the patient’s caregiver. The tracking and analysis of seizures can be shared with clinicians & allows to personalize treatment. Main objective of this feasibility study is the development of a comprehensive business plan to evaluate the opportunities & risks of introducing ESPS into the homecare market. All project activities follow the Healthcare Innovation Cycle methodology & are structured around 4 development pillars - Technology, Market & Business, Clinical and Regulatory. The introduction of ESPS is prone to disrupt the epilepsy market by reducing treatment costs per patient by up to 70%. Thus, saving 14B€ in health care costs in Europe alone and creating a major shift towards preventive & personalized treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

APS (2019)

On-site and On-demand Flexible Packaging System

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More